NCLAT interim order in Supha Pharmachem CIRP matter

Court stay obtainedRegulatory & Legal View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹0.31

prior close

₹0.32

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.2% vs market

Trading & Distributors peers, median of 132sector+0.0%+0.0% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and in line with its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.2-0.2+0.0+0.0

Next day

+0.0+1.0-1.0-0.0+0.0

+3.2+0.7+2.5+0.0+3.2

+6.5+0.9+5.6-0.5+7.0

+9.7+0.2+9.5-1.0+10.6

+9.7-1.8+11.5-2.1+11.8

+0.0+1.4-1.4-1.9+1.9

15d

+6.5-0.6+7.1-2.4+8.8

+9.7+1.5+8.2-1.9+11.6

-6.5+4.5-11.0-3.9-2.5

-12.9+3.1-16.0-4.2-8.7

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 132Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supha Pharmachem (formerly Remedium Lifecare) is undergoing CIRP. NCLAT declined to entertain Medec Infra's appeal challenging its exclusion from the Committee of Creditors as a related party, but granted interim protection until 29 June 2026: the CoC cannot vote on any resolution plan and no immovable property of the company can be sold. The main matter is listed before the Adjudicating Authority on 29 June 2026.

Likely market impact

CIRP process delayed; resolution plan voting and asset sales frozen until 29 June 2026 hearing. Continued uncertainty for shareholders.